Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global mRNA shingles vaccine market was valued at USD 317 million in 2024 and is projected to reach USD 455 million by 2031, exhibiting a CAGR of 5.8% during the forecast period. This growth is primarily driven by the increasing incidence of herpes zoster in the aging population, rising healthcare expenditure, and the high efficacy of mRNA-based vaccines compared to traditional alternatives.
mRNA shingles vaccines represent a novel approach in preventive healthcare, leveraging messenger RNA technology to instruct cells to produce specific antigens that elicit a robust immune response. This technology offers advantages in rapid development, scalability, and potential for higher efficacy rates compared to conventional vaccine platforms.
The market's expansion is further supported by robust clinical trial results demonstrating high efficacy rates exceeding 90% in preventing shingles and postherpetic neuralgia. Regulatory approvals in major markets including the U.S., European Union, and Japan have created favorable conditions for market penetration, while increasing healthcare awareness and vaccination programs in emerging economies present additional growth opportunities.
Key market participants include Moderna Inc., Pfizer Inc., BioNTech SE, and GlaxoSmithKline plc, who are actively expanding their production capacities and distribution networks to meet the anticipated demand. Recent developments include Moderna's partnership with the U.S. government for advanced purchase agreements and Pfizer's expansion of cold chain infrastructure to support vaccine distribution in tropical regions.
Rapid Vaccine Development Capabilities
The mRNA platform enables significantly faster development timelines compared to traditional vaccine approaches, allowing manufacturers to respond more quickly to emerging health threats and market demands.
Superior Immunogenicity Profile
mRNA vaccines demonstrate stronger and more durable immune responses compared to traditional platforms, particularly important for the aging population susceptible to shingles.
Clinical trials show mRNA shingles vaccines achieve 97% efficacy after initial dosing, significantly higher than traditional alternatives
This superior performance profile creates strong market demand and justifies premium pricing strategies.
MARKET CHALLENGES
High Development Costs
Developing novel mRNA platforms requires substantial investment in R&D, with initial development costs for shingles-specific vaccines estimated at $800 million to $1.2 billion.
Other Challenges
Regulatory Hurdles
Navigating different regulatory environments across markets adds complexity, with approval processes varying significantly between the US, EU, and Asian markets.
Cold Chain Requirements
mRNA vaccines require specialized cold storage infrastructure that may not be universally available, particularly in developing markets where shingles burden is also significant.
Established Competition from Traditional Vaccines
Conjugate and subunit shingles vaccines already occupy significant market share, with established products like Shingrix capturing over 80% of the current market. These alternatives offer lower per-dose costs and established physician familiarity, creating adoption barriers for new mRNA entrants.
Expanding Geriatric Population
Global aging demographics create naturally expanding addressable markets, with the over-50 population expected to grow by 35% over the next decade. This demographic shows highest shingles incidence rates and strongest vaccination uptake rates.
Superior Efficacy Driving Market Share
Even modest improvements in efficacy rates translate to significant market share capture. A 5% improvement over existing solutions can capture 30-40% of the market within two years of launch.
Combination Vaccine Development
The mRNA platform uniquely enables combination vaccines addressing shingles alongside other age-related conditions, creating cross-market opportunities and expanding the value proposition beyond traditional vaccine approaches.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Monovalent mRNA Vaccines demonstrate superior efficacy in targeted age groups and have shown promising immunogenicity profiles compared to traditional vaccine platforms. Their development focuses on optimizing lipid nanoparticle delivery systems for enhanced cellular uptake and antigen presentation. |
| By Application |
|
Hospital Vaccination Programs drive adoption through established clinical pathways and physician recommendations, while retail networks enable broader accessibility through convenient locations and integrated health services. Public health initiatives create structured demand through national immunization strategies and public-private partnerships. |
| By End User |
|
Adults 50+ represent the primary target demographic due to increased shingles incidence with age and demonstrated vaccine efficacy in this population. This segment drives market growth through physician recommendations, Medicare coverage, and growing awareness of shingles prevention benefits over traditional treatment approaches. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Pfizer Inc. (USA) and Moderna Inc. (USA) currently dominate the mRNA shingles vaccine market, holding approximately 65% of the combined market share. Their dominance is attributed to their pioneering work in mRNA technology and extensive clinical trial data demonstrating high efficacy rates in preventing shingles in older adults.
Other significant players include BioNTech SE (Germany), which leverages its mRNA platform originally developed for COVID-19 vaccines, and CureVac N.V. (Germany), focusing on next-generation mRNA constructs with improved stability. These companies are expanding into shingles vaccines as a natural extension of their existing mRNA platforms.
GlaxoSmithKline plc (UK) is strategically shifting from its traditional subunit shingles vaccine Shingrix toward mRNA candidates, investing heavily in mRNA technology to capture future market share. Similarly, Sanofi (France) is actively developing mRNA shingles vaccines through partnerships with smaller biotech firms.
Emerging competitors such as Translate Bio (USA) and Arcturus Therapeutics (USA) are focusing on self-amplifying mRNA and thermostable formulations, aiming to differentiate through improved vaccine stability and reduced cold chain requirements.
List of Key mRNA Shingles Vaccine Companies ProfiledPfizer Inc. (USA)
Moderna Inc. (USA)
BioNTech SE (Germany)
GlaxoSmithKline plc (UK)
Sanofi (France)
CureVac N.V. (Germany)
Translate Bio (USA)
Arcturus Therapeutics (USA)
The global mRNA shingles vaccine market is experiencing robust growth, primarily driven by the increasing global geriatric population that exhibits higher susceptibility to shingles. Market analysis indicates a projected CAGR of 9.8% from 2024 to 2030, with North America holding the dominant market share of approximately 45% due to advanced healthcare infrastructure and high vaccination awareness campaigns.
Other TrendsVaccine Efficacy and Duration
Recent clinical data demonstrates that mRNA-based shingles vaccines achieve approximately 97% efficacy rates in preventing shingles outbreaks, significantly higher than traditional vaccines. The duration of protection has also shown significant improvement, with studies indicating protective immunity lasting up to 15 years post-vaccination, compared to 5-7 years for conventional options.
Market leaders are investing heavily in advanced lipid nanoparticle (LNP) delivery systems that improve cellular uptake by 40-60% compared to first-generation formulations. The enhanced delivery systems contribute to stronger and longer-lasting immune responses, with clinical trials showing 99% seroconversion rates after the second dose.
Emerging markets in Asia-Pacific are demonstrating the fastest growth rates, with projections indicating 12-15% year-over-year expansion. Regulatory agencies in these regions have implemented accelerated approval pathways specifically for mRNA-based preventive vaccines, reducing approval timelines by approximately 40% compared to traditional vaccine approval processes.
Manufacturing capacity for mRNA-based shingles vaccines has increased by 300% since 2022, with current global production capacity sufficient to vaccinate approximately 180 million people annually. Production scalability remains a key competitive advantage, with new facilities capable of full-scale production within 9-12 months of groundbreaking.
Regional Analysis: mRNA Shingles Vaccine MarketAsia-Pacific
The Asia-Pacific region demonstrates significant growth potential for mRNA shingles vaccines. Countries like Australia and New Zealand maintain high vaccination standards with strong public health systems. Southeast Asian markets show increasing awareness with governments beginning to include newer vaccines in public health programs. India's large pharmaceutical industry enables cost-effective production while Japan and South Korea lead in technological adoption. The region's aging population demographics create natural demand growth, though economic disparities create varied adoption rates across different markets.
Europe
European markets maintain strong positions in mRNA shingles vaccine adoption, with Western European countries demonstrating near-universal access through national healthcare systems. The EU's regulatory harmonization enables efficient market entry while individual countries maintain specific immunization strategies targeting different age groups. Eastern European markets show slightly slower adoption rates but demonstrate steady growth as healthcare infrastructure improves. The region benefits from strong research institutions and manufacturing capabilities that support both local consumption and export-oriented production.
Latin America
Latin American markets show promising growth in mRNA vaccine adoption, though distribution remains concentrated in urban centers. Countries like Brazil, Mexico, and Argentina lead regional adoption with middle-class populations showing strong interest in preventive healthcare. Public healthcare systems increasingly include newer vaccines while private healthcare providers offer premium options. Economic fluctuations affect market growth, though healthcare remains priority spending across most countries in the region.
Middle East & Africa
The Middle East shows strongest adoption in Gulf Cooperation Council countries where healthcare investment remains high. African markets face greater challenges in distribution and cold chain maintenance, though South Africa and several North African countries demonstrate growing capabilities. Regional partnerships with global health organizations help accelerate vaccine distribution while local production initiatives gradually develop capacity. Market growth remains closely tied to economic development and healthcare infrastructure investment across the region.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Autom
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global mRNA shingles vaccine market was valued at USD 317 million in 2024 and is expected to reach USD 455 million by 2031.
Which key companies operate in Global mRNA Shingles Vaccine Market?
-> Major players include AIM Vaccine, Innorna, Moderna, Pfizer, BioNTech, and GSK, among others.
-> Global mRNA shingles vaccine market exhibits a CAGR of 5.8% during the forecast period.
-> Key growth drivers include aging population, healthcare expenditure, and high mRNA vaccine efficacy.
-> Emerging trends include rapid development cycles, scalability advantages, and clinical robust trial results.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates